Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Immunicon logo — Pioneering cell-based diagnostic solutions to empower physic...

Immunicon

Pioneering cell-based diagnostic solutions to empower physicians with timely and accurate cancer insights.

Founded 1983 Series F Total: $53.75M Biotechnology, Health Care

General Information

Company Name Immunicon
Founded Year 1983
Industries Biotechnology, Health Care
Funding Stage Series F
Social

BounceWatch is an independent company data service, not affiliated with Immunicon. To contact Immunicon, visit immunicon.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Immunicon compare?

A PDF of Immunicon and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Immunicon soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Immunicon

Immunicon, a pioneer in cell-based diagnostic solutions, is revolutionizing the field of cancer diagnosis and treatment. The company's flagship product, CellTracks, enables the identification, counting, and characterization of tumor cells in blood samples, providing crucial insights to physicians and scientists at an early stage. In 2003, the company received a significant boost with a $24.75M Series F investment from a consortium of prominent investors including Canaan Partners, TL Ventures, Burrill & Company, Wheatley Partners, and Johnson & Johnson Development Corporation. This investment has positioned Immunicon for significant growth and market penetration. With an impressive track record dating back to 1983, Immunicon continues to expand its applications beyond cancer diagnostics, foreseeing opportunities in areas such as cardiovascular and infectious diseases. Teaming up with Veridex, LLC, (a Johnson & Johnson company), the company has demonstrated its commitment to delivering innovative solutions with real-world impact.

Business keywords: Cell-based diagnostics, Cancer insights, Diagnostic products, Cancer research, Clinical practices, Tumor cell identification, Blood sample analysis, FDA approval process, Collaboration with Johnson & Johnson, Metastatic breast cancer management, Cancer drug development, Cardiovascular diseases, Infectious diseases, Medical technology, Healthcare innovation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series F $24.75M 5
Canaan Partners TL Ventures Burrill & Company
Canaan Partners, TL Ventures +3
10 Jul 2003
Series F $29.00M -
01 Jun 2001

Immunicon Alternatives & Competitors

View All Alternatives
Immunicon vs
Sopherion Therapeutics
Sopherion Therapeutics

Innovating metastatic breast cancer treatment through advanced nanotechnology solutions.

Series C
Biotechnology, Health Care
Immunicon vs
Pathwork Diagnostics
Pathwork Diagnostics

Pioneering molecular diagnostics for oncology with the first FDA-cleared microarray-based gene expre...

Venture round
Biotechnology, Health Care
Immunicon vs
Polaris Biology
Polaris Biology China

Meet the next resolution in medicine

Series B
15 employees
Biopharma, Biotechnology
Also compare with: Immunicon vs ANGLE ANGLE View all alternatives

FAQ About Immunicon

Pioneering cell-based diagnostic solutions to empower physicians with timely and accurate cancer insights.
Immunicon was founded in 1983.
Immunicon operates in Biotechnology and Health Care. Its work centres on Cell-based diagnostics, Cancer insights, Diagnostic products and Cancer research.
Immunicon has completed 2 funding rounds, raising a total of $53.75M. The latest funding stage is Series F.
Top alternatives and competitors to Immunicon include Sopherion Therapeutics, Pathwork Diagnostics, Polaris Biology, Adaptive Biotechnologies Corp., ANGLE. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Immunicon and Sopherion Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Immunicon, https://www.bouncewatch.com/company/immunicon, updated 17 July 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout